SCHEMBL16190418

CC1C(O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]1C(O)[C@H](O)C(CO)O[C@@H]1OCC1O[C@@H](O[C@@H]2C(CO)O[C@@H](O[C@@H]3C(CO[C@@H]4O[C@@H](C)[C@@H](O)C(O)C4O)O[C@@H](C)[C@@H](C)C3O)[C@@H](C)C2O)[C@H](O)C(O[C@H]2O[C@H](CO)[C@@H](O)C(O)C2O[C@@H]2OC(CO)[C@@H](O[C@@H]3OC(CO[C@]4(C(=O)O)C[C@@H](O)[C@@H](N)C([C@H](O)[C@H](O)CO)O4)[C@H](O)C(O)[C@@H]3O)C(O)[C@@H]2C)[C@@H]1O

nearest known ligand 0.49

Predicted protein targets (top 6)

	gene	UniProt	supporting neighbours	confidence
▸	SIGLEC7	Q9Y286	6/20	0.49

▸	SELP	P16109	2/20	0.45

▸	SELL	P14151	2/20	0.45

▸	MAG	P20916	5/20	0.44

▸	SELE	P16581	4/20	0.43

▸	CD209	Q9NNX6	1/20	0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL16312408	1.00	SIGLEC7 (0.49)	SIGLEC7SELPSELLMAGSELE
SCHEMBL16348242	1.00	SIGLEC7 (0.49)	SIGLEC7SELPSELLMAGSELE
SCHEMBL16190420	0.99	SIGLEC7 (0.49)	SIGLEC7SELPSELLMAGSELE
SCHEMBL16312406	0.99	SIGLEC7 (0.49)	SIGLEC7SELPSELLMAGSELE
SCHEMBL18333527	0.99	SIGLEC7 (0.49)	SIGLEC7SELPSELLMAGSELE
SCHEMBL17199596	0.99	SIGLEC7 (0.49)	SIGLEC7SELPSELLMAGSELE
SCHEMBL16348244	0.99	SIGLEC7 (0.49)	SIGLEC7SELPSELLMAGSELE
SCHEMBL16312448	0.99	SIGLEC7 (0.49)	SIGLEC7SELPSELLMAGSELE
SCHEMBL18333570	0.97	SIGLEC7 (0.49)	SIGLEC7SELPSELLMAGSELE
SCHEMBL15849918	0.97	SIGLEC7 (0.49)	SIGLEC7SELPSELLMAGSELE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-9441024-B2	Glycosylated polypeptide and drug composition containing said polypeptide	GLYTECH, INC. (JP)	2016-09-13	—	—	US	disclosed
US-20150306235-A1	SUGAR CHAIN-ATTACHED LINKER, COMPOUND CONTAINING SUGAR CHAIN-ATTACHED LINKER AND PHYSIOLOGICALLY ACTIVE SUBSTANCE OR SALT THEREOF, AND METHOD FOR PRODUCING SAME	GLYTECH INC (JP)	2015-10-29	—	—	US	disclosed
US-20150299337-A1	GLYCOSYLATED LINKER, COMPOUND CONTAINING GLYCOSYLATED LINKER MOIETY AND PHYSIOLOGICALLY ACTIVE SUBSTANCE MOIETY OR SALT THEREOF, AND METHODS FOR PRODUCING SAID U OR SALT THEREOF	GLYTECH INC (JP)	2015-10-22	—	—	US	disclosed
US-20140315800-A1	Glycosylated Polypeptide and Drug Composition Containing Said Polypeptide	GLYTECH, INC. (JP)	2014-10-23	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20150299337-A1	GLYCOSYLATED LINKER, COMPOUND CONTAINING GLYCOSYLATED LINKER MOIETY AND PHYSIOLOGICALLY ACTIVE SUBSTANCE MOIETY OR SALT THEREOF, AND METHODS FOR PRODUCING SAID U OR SALT THEREOF	CD44, CSGALNACT1, UGGT1	SIGLEC7 8/4885SELP 156/4885SELL 92/4885
US-20150306235-A1	SUGAR CHAIN-ATTACHED LINKER, COMPOUND CONTAINING SUGAR CHAIN-ATTACHED LINKER AND PHYSIOLOGICALLY ACTIVE SUBSTANCE OR SALT THEREOF, AND METHOD FOR PRODUCING SAME	SI, ENGASE, DNPEP	SIGLEC7 29/4885SELP 331/4885SELL 370/4885
US-20140315800-A1	Glycosylated Polypeptide and Drug Composition Containing Said Polypeptide	GIPR, SSTR3, SSTR4	SIGLEC7 92/4885SELP 220/4885SELL 188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.